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1. Introduction 
The thalassemia is a widespread with about 5% of the world population affected by it and is 
found in some 60 countries, with the highest prevalence in the Mediterranean region, parts 
of North and West Africa, the Middle East, the Indian subcontinent, southern Far East and 
south-eastern Asia, together comprising the so-called thalassemia belt. In western countries, 
thalassemia affects mostly individuals whose ancestry is traceable to high prevalence areas. 
As an example, there are around 1,000 cases of ǃ-thalassemia major in the United States, 
most of whom are descendants of Mediterranean, Asian Indian, South Asian or Chinese 
ancestors. This figure is even less than half of the number of ǃ-thalassemic patients in Fars 
Province, a region only 120,000 km 2 large in southern Iran (Haghshenas and Zamani, 1997; 
Rahim et al., 2007). The gene frequency of ß-thalassemia, however, is varies from area to 
area, having its highest rate of more than 10% around the Caspian Sea and Persian Gulf. The 
prevalence of the disorder in other areas is between 4-8% (Rahim and Abromand, 2008). 
There are many genes coding for the globins. They are found on chromosome 11 (ǃ-globin 
cluster) or chromosome 16 (ǂ-globin cluster) figure1. 
1.1 Beta-Thalassemia 
Beta-Thalassemia, one of the most widespread genetic diseases in the world, is a common 
autosomal recessive disorder caused by point mutations in the ß- globin gene that is located 
as a cluster on the short arm of chromosome 11 (Weatherall et al., 1989; Sack, 1999; Oliveri, 
1999). More than 200 different mutations affecting diverse levels of beta-globin genes 
expression have so far been identified (Trent, 1997; Ho and Thein, 2000). South-western 
region of Iran also represented various ß-thalassemia mutations (Figure 2).   Different 
strategies of classification individuals genotypes by ß-globin gene cluster and cloning 
nucleotides sequencing lead to identification of several mutations in Mediterranean (Orkin 
et al., 1982), Asian Indians (Kazazian et al., 1984, Ohba et al., 1997), American Blacks 
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(Antonarakis et al., 1984) and Chinese (Cheng et al., 1984). The global distribution indicates 
a high prevalence in a belt around the earth, which is around the 40th parallel in the 
Mediterranean area but eastwards moves further south, reaching the equator in Indonesia. 
More than two million carriers of ß-thalassemia live in Iran. The Iranian populations are 
mixture of different ethnic groups. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Two globin gene clusters including ǂ- and ǃ- represented here. 
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1.2 Alpha thalassemia 
Alpha thalassemia disorders are a group of hereditary anemias caused by absent or 
decreased production of the alpha chain of hemoglobin (Hb) (Vichinsky, 2009). freeAll 
affected individuals have a variable degree of anaemia (low Hb), reduced mean corpuscular 
hemoglobin (MCH/pg), reduced mean corpuscular volume (MCV/fl) and a 
normal/slightly reduced level of HbA2. Molecular analysis is usually required to confirm 
the hematological observations (especially in silent alpha thalassemia and ǂ-thalassemia 
trait). A single gene, two-gene, three-gene or four-gene deletions result in alpha thalassemia 
silent carrier status, thalassemia trait (minor), HbH, and hemoglobin Bart’s (Hb Bart’s), 
respectively (Figure 3).  
 
 
 
 
 
 
 
 
 
Fig. 2. Different ß-thalassemia mutations detected in our region of study (South-western 
region of Iran), different explained groups are carrier, which represents the heterozygous 
type; Major, which represents the homozygous type; Variants, which represents the 
hemoglobin variants 
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Fig. 3. Different ǂ -thalassemia mutations detected in our region of study (South-western-
region of Iran), different explained groups are carrier, which represents the heterozygous 
type; Major, which represents the homozygous type; HbH, Hemoglobin H disease 
1.3 Thalassemia intermedia 
Thalassemia intermedia are a clinical phenotype which displays marked genotypic 
variability in different populations or ethnic groups (Panigrahi et al., 2009). This disorder is 
a clinical designation often used to characterize individuals who are homozygous for b-
thalassemia genes but maintain hemoglobins of 6–9 g/dL without regular transfusions 
(Galanello et al., 2001). They have more severe RBC morphological abnormalities than the 
trait, as well as varying degrees of splenomegaly, thrombosis and skeletal changes (Taher et 
al., 2008). 
1.4 Hemoglobin H (Hb H) 
Hemoglobin H (Hb H) disease is the most common form of thalassemia intermedia. Hb H 
(beta4) disease results from double heterozygosity for alpha(0)-thalassemia due to deletions 
that remove both linked alpha-globin genes on chromosome 16, and deletional alpha(+)-
thalassemia from single alpha-globin gene deletions (--/-alpha). However, Hb H disease 
may occur from interactions between alpha (0)-thalassemia with nondeletional mutations or 
with abnormal hemoglobins such as Hb Constant Spring, Hb Paksé, Hb Quong Sze, and Hb 
Pak Num Po (Fucharoen and Viprakasit, 2009).  
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1.5 Hemoglobin (Hb) Bart's 
Hemoglobin (Hb) Bart's hydrops fetalis is a generally fatal intrauterine condition associated 
with homozygous alpha (0)-thalassemia. It is moderately insoluble, and therefore 
accumulates in the red blood cells (Karnpean et al., 2009; Singer, 2009). 
1.6 Simultaneous α-and β-thalassemia 
Some case of complex beta- and alpha-thalassemia coinheritance is described. The chance of 
finding an individual with co-inheritance of ǂ0- and ǃ-thalassemia is theoretically 1: 1000. In 
other words, one in every 25 b-thalassemia carriers co-inherits a0- thalassemia (Rahim, 2010; 
Rahim et al., 2008). Routine screening testing, such as mean cell volume (MCV) and Hb A2 
level, cannot distinguish double heterozygotes for ǂ and ǃ-thalassemia from the pure ǃ-
thalassemia heterozygotes. The ǂ0-thalassemia can be distinguished simply from double ǂ0- 
and ǃ-thalassemia by a normal Hb A2 level (Table 1).  
 
Case Sex 
Age 
(Y) 
Hb 
(g/dl) 
MCV(fl) MCH(pg) HbF(%) HbA2(%)
ǂ-
genotype
ǃ-
genotype 
HbH 
1 M 24 13.9 72.1 23.4 1.1 5.3 - ǂ3.7/ ǂǂ A - 
2 M 32 11.7 70.7 22.6 0.4 5.1 - ǂ3.7/ ǂǂ B - 
3 M 29 11.4 73.0 22 0.5 5.1 
- ǂ3.7/ - 
ǂ3.7 C - 
4 F 27 11.9 71.5 22.6 1.5 4.2 ǂǂ / - ǂ4.2 D - 
5 F 30 10.4 65.0 21 1.4 4.5 - ǂ3.7/ ǂǂ E - 
6 F 25 11.7 61.4 19.8 0.9 4.3 - ǂ3.7/ ǂǂ F - 
7 F 23 13.2 69.7 23.2 1.3 5.3 
ǂǂ / - - 
MED 
G - 
8 M 29 11.5 75.5 23.2 1.9 4.9 ǂǂ / - ǂ4.2 H - 
9 M 27 13.3 67.3 22.6 1.4 5.5 
ǂǂ / - - 
MED 
I + 
10 M 29 11.1 69.5 23.8 0.9 5.4 
ǂǂ / - - 
MED 
J + 
A, ǃIVS 1-5 /ǃN; B, ǃIVS 1-25 /ǃN; C, ǃIVS 2-1 /ǃN; D, ǃCD8(-AA)/ǃN; E, ǃCD121(G-C)/ǃN; F, ǃCD6(CTC-GAG)/ǃN;G, ǃIVS 2-1 /ǃN; 
H, ǃCD121(G-C)/ǃN;I, ǃCD41/42)/ǃN ; J, ǃCD8(-AA)/ǃN 
Table 1. Hematologic and genotypic findings in the 10 double heterozygotes for ǂ- and ǃ-
thalassemia 
1.7 Co-inheritance of α-and hemoglobin variants 
The chance of finding an individual with co-inheritance of ǂ0- thalassemia with different 
hemoglobin variants is also presented. In other words, this chance and presentation is rare 
(Rahim, 2009). 
2. Diagnosis 
The key to successful detection and characterization of the hemoglobinopathies, particularly 
the thalassemias, is the initial hematological data. The clue for a thalassemia comes with a 
low mean corpuscular volume (MCV) or mean corpuscular hemoglobin (MCH). Although 
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iron deficiency is the other explanation for a low MCV or MCH, it is likely that this finding 
will point to thalassemia in regions of countries with at-risk ethnic populations (Table 2). 
  
 
 
*Includes hemoglobin S (HbS), hemoglobin C (HbC) and hemoglobin DPunjab (HbDPunjab) 
Table 2. Hematological parameters in different groups with microcytic hypochromic anemia 
2.1 Differential diagnosis of beta-thalassemia  
We can differentiate ǃ -thalassemia from other disorders such as iron deficiency anemia 
with the help of discriminate indices including Mentzer Index, England and Fraser Index, 
Srivastava Index, Green and King Index, Shine and Lal Index, red blood cell (RBC) count, 
red blood cell distribution width index (RDWI), Mean Density of Hemoglobin per Liter of 
blood (MDHL) and mean cell hemoglobin density (MCHD) (Rahim and Keikhaei, 2009). If 
iron deficiency is present, it is essential to correct this and then repeat the full-blood count 
and all other investigations. The first step after the initial abnormal blood count is to exclude 
iron deficiency and if present, to treat it. The blood count is then repeated and if the 
MCV/MCH remains low, a thalassemia is most likely. Therefore, ferritin levels (and if 
necessary serum iron, iron binding capacity and percentage saturation) are sought. This is 
recommended because at times, particularly during pregnancy, it is possible that iron stores 
will be low or, in the presence of iron deficiency, it is possible that the MCV or MCH are 
influenced by the iron deficiency. It is also occasionally seen that the HbA 2 level can be 
falsely lowered by iron deficiency. In this context there are special hemoglobin tests which 
may help in the primary detection scenarios (Table 3).    
2.2 Molecular diagnostic methods 
Almost all the methods for DNA analysis of the hemoglobinopathies used today are based 
on the polymerase chain reaction (PCR). Different well-known and applied methods have 
been described in table 4. Therefore whether a mutation is a deletion, a rearrangement or a 
point mutation, a similar test will be performed with the variability and specificity coming 
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Table 3. Special hematologic tests requested once a hemoglobinopathy is suspected based on 
family history and/or full-blood count. 
from the primers used. The sensitivity and specificity of PCR has revolutionized the 
molecular diagnostic field. It has almost eliminated the use of radioactive isotopes for 
detecting sequences and has enabled diagnosis to be made on much smaller quantities of 
DNA. The PCR-based techniques used in hemoglobin diagnostics include allele-specific 
oligonucleotide (ASO) hybridization or dot-blot analysis, reverse dot-blot analysis, allele-
specific priming or amplification refractory mutation system (ARMS), restriction enzyme 
analysis, amplification created restriction analysis, mutagenically separated PCR and gap-
PCR. These PCR-based techniques are useful for identifying a known mutation; PCR-based 
approaches for scanning or screening for unknown mutations take advantage of altered 
conformation of single-stranded DNA and include denaturing gradient gel electrophoresis 
(DGGE), single-strand conformation polymorphism (SSCP) and heteroduplex analysis. The 
characteristic altered patterns of migration and their position in the scanning methods act as 
a guide for the location of the mutation, targeting the region for identification by other 
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means. The ultimate method of mutation identification is by direct sequence analysis of 
specifically amplified DNA. In the last decade, the use of automated sequencers has led to 
nonradioactive, more robust and more rapid sequencing, making it suitable as a routine 
diagnostic tool. Direct sequencing analysis is particularly applicable to the globin genes 
which are compact and relatively small (1.2-1.6kb) with most of the point mutations within 
the gene or its flanking sequences (Fakher et al., 2006). 
Southern blotting is one of the few non-PCR based molecular techniques that still have a 
significant role to play in the molecular diagnosis of the hemoglobinopathies. It is very 
useful in the screening for large deletions or rearrangements and is essential in 
characterizing novel deletions. The more common deletions can be detected by gap-PCR 
once the deletion break points have been defined and specific primers flanking the deletion 
designed. Each of these techniques has its own limitations; the particular repertoire chosen 
by a laboratory for molecular diagnosis of the hemoglobinopathies depends on the spectrum 
of mutations encountered in their catchment area and the technical expertise available in the 
diagnostic laboratory. It is good practice for any DNA diagnostic laboratory to have at least 
two alternative methods for detecting each mutation (Vrettou et al., 2003). 
2.3 Prenatal Diagnosis (PND) & Foetal DNA analysis 
Although historically, the prevention program, abortion, was considered unacceptable in 
Iran, intensive consultation led to the clerical approval of induced abortion in cases with ǃ- 
thalassemia major in 1997, and a nationwide prevention program with screening, counseling 
and prenatal diagnosis (PND) network has been developed (Najmabadi et al., 2006 ;Rahim 
et al., 2007) (Table 4). Many laboratories offering DNA diagnostics of the Hb disorders are 
also involved in analysis of fetal DNA for the prenatal diagnosis of these disorders. Fetal 
DNA is usually and preferably, obtained through chorionic villus sampling in the first 
trimester of pregnancy (10-12 weeks). Chorionic villus sampling provides a good yield of 
DNA which is isolated using conventional methods of phenol chloroform extraction after 
careful microscopic dissection to remove any contaminating maternal deciduas. 
Occasionally, if the sample is too small, it may need to be cultured increasing the risk of 
maternal contamination. Amniocytes obtained in the second trimester can also be used as a 
source of fetal DNA but the fetal cells are often contaminated with maternal cells and the 
results have to be interpreted with caution after analysis for maternal contamination. 
Every prenatal diagnosis should be accompanied by copies of haematology results of the 
parents and prior confirmation of the parental phenotypes and genotypes. The PCR-based 
techniques that best suit the expertise of the laboratory are then used to screen for the 
presence of the parental mutations in the fetal DNA. Parental, appropriate positive and 
negative controls must always be included in the investigations. A limited number of PCR 
cycles (25-28) should be performed to avoid amplification of any minor DNA species and to 
minimize amplification of any contaminating maternal DNA. As an added precaution, 
maternal DNA contamination should be checked for by using polymorphic DNA markers 
including the variable tandem repeats (VNTRs) such as ApoB and the short tandem repeats 
or micro satellites. This is particularly important when the fetal genotype is the same as the 
maternal genotype. Fetal DNA analysis should also be performed in duplicate and 
confirmed by an independent PCR-based technique. To confirm maternal DNA 
contamination we used polymorphic DNA markers including the variable tandem repeats 
(VNTRs) in all cases. 
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Table 4. Globin mutations identified by reverse- hybridization and DNA sequencing in 254 
thalassemia patient and prenatal DNA sample were initially tested for 22 common 
mutations by reverse – hybridization (Fakher et al., 2006). 
3. Discussion 
Iran is a country which has a population with a different ethnic identity and different 
languages. As we saw mutation in ß-globin gene will lead to thalassemia. Although, all this 
mutations were found in coastline areas but their geographic distribution has special 
characteristic properties. In most parts of the world, a small number of thalassemia 
mutations predominant and the most common ones tend to be those that are geographically 
the most widespread and presumably also the oldest. For instance, in China and Southeast 
Asia, four alleles account for 91% of the genes (Kazazian et al., 1986), and in the 
Mediterranean Basin, six mutation account for 92% of the genes (Najmabadi et al., 2002). 
However, mutation 619 bp deletion is predominant in India or mutations IVS I-110 and IVS 
II-1 are most predominant in Arab populations (El-Hazmi et al., 1995). Because of Wars and 
trade off between different countries in the past years there was exchange of genetic 
materials between different populations. In one study it show that IVS II-1, IVS I-110, IVS I-
1, and CD 8/9. These mutations are the most frequent in Iran and IVS II-1(24%) is most 
predominant in Khuzestan (Rahim and Abromand, 2008). In a similar work on 1217 patients 
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with ß- thalassemia the most predominant mutation in North part of Iran was IVS II-1(34%) 
and in South part was IVS I-5(%) (Najmabadi et al., 2002).  
Najmabadi et al (2002), have studied ß -globin mutations and claimed the most common ß -
globin mutations is IVS I-130 (G-C), which was identified in six subjects from the North of 
Iran, three subjects from the Southwest, as well as in one DNA of unknown geographical 
origin.  We have found that most predominant in South was IVSII-I (34%) follows by IVS I-
110(15.7%) and CD 8/9(13.3%) (Rahim and Abromand, 2008). Previous research work 
showed most predominant mutation in Pakistan is IVS I-5(37%) therefore this mutation is 
most predominant in Sistan-Baloochestan (44.8%)(Southeast of Iran) because it is a 
neighborhood area to Pakistan (Kazazian et al., 1984). In a work done on thalassemia 
patients in Hormozgan (Southern part of Iran) claimed that most predominant mutation 
there is IVS I-5(69%) followed by IVS II- 1(9.6%) (Yavarian et al., 2001).  
Research work done in 8 Gulf (Arab) Countries showed that most predominant mutations 
are IVS I-110 and IVS II-1 followed by IVS I-5, CD39, CD6, IVS I(3' end)-25 bp del (Adekile et 
al., 2005). Our finding was similar to the work done in Kuwait which showed 6 mutations 
are most predominant involve IVS II-1, IVS I-6, CD39, IVS I-110, CD8, IVS I-1(all give 64%) 
and followed by another 2 involve CD44, CD 36/37 (Kurd, Iranian types) that give 10% of 
the population. We detected different ß-thalassemia mutations in the studied chromosomes 
and 5 different areas from Iran which showed IVS-II-I (G → A) was the predominant 
mutation found in all ethnic regions. . The presence of such a high frequency of various local 
mutants alleles confirms support for a role of non-isolating genetically areas. In likelihood, 
both founder effect and natural selection caused by migration from neighboring areas have 
complemented each other to produce the high frequency of unique alleles within each 
region (Figure 4).  
 
 
Fig. 5. The origin of mutant alleles with high frequency within different parts of Iran. The 
most frequent beta-gene mutations in each ethnic region indicated individually. 
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